When was Mynvax founded?

Mynvax was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Mynvax located?

Mynvax is headquartered in Bengaluru, India. It is registered at Brigade MLR Centre, No 50, 3rd Floor, Vani Vilas Road, Basavanagudi, Bangalore, Bangalore, Karnataka, India, 560004.

Which legal entities is Mynvax associated with?

Mynvax is associated with MYNVAX PRIVATE LIMITED.

How many employees does Mynvax have?

As of Aug 31, 2025, Mynvax has 29 employees, reflecting a 4% year-over-year growth in headcount.

Is Mynvax a funded company?

Mynvax is a funded company, having raised a total of $9.82M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 07, 2018.

How much is Mynvax worth?

The latest valuation of Mynvax is $***** as of Aug 13, 2021.

When was the latest funding round of Mynvax?

Mynvax's latest funding was a $***** Series A round on May 24, 2024, with participation from 2 investors.

What is the annual revenue of Mynvax?

Annual revenue of Mynvax is less than ₹10 Cr as on Mar 31, 2025

Where does Mynvax rank among its competitors?

Mynvax ranks 51st amongst 293 active competitors, of which 76 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Leyden Labs, which secured $45.5M in Jun, 2026.

Who are the top competitors of Mynvax?

Mynvax's top competitors include HOOKIPA Pharma, Vaxart and Atea. Among them, Leyden Labs secured the most recent funding round in June, 2026.

Mynvax - 2026 Company Profile, Team, Funding, Competitors & Financials

Mynvax is a series A company based in Bengaluru (India), founded in 2017 by Raghavan Varadarajan and Gautham Nadig. It operates as a Developer of novel recombinant vaccines to fight the human influenza virus and COVID19. Mynvax has raised $9.82M in funding from investors like Accel, Nadig Advisors and Baldota Family Office, with a current valuation of $*****. The company has 293 active competitors, including 76 funded and 73 that have exited. Its top competitors include companies like HOOKIPA Pharma, Vaxart and Atea.

Company Details

Developer of novel recombinant vaccines to fight the human influenza virus and COVID19. The company has developed a vaccine by genetically engineering a domain of the surface spike glycoprotein of the SARS-CoV-2 virus, called the Receptor Binding Domain which attaches itself to the Ace2 receptor on the surface of the target cells in the human respiratory tract.

Website: mynvax.com
Registered Address: Brigade MLR Centre, No 50, 3rd Floor, Vani Vilas Road, Basavanagudi, Bangalore, Bangalore, Karnataka, India, 560004

Key Metrics

Founded Year

2017

Location

Bengaluru, India

Stage

Series A

Total Funding

$9.82M in 5 rounds

Latest Funding Round

Series A, May 24, 2024, $*****

Post Money Valuation

$***** as on Aug 13, 2021

Investors

Lakshminarayanan Subramanian & 73 more

Ranked

51^st among 293 active competitors

Annual Revenue

0 - ₹10 Cr as on Mar 31, 2025

Employee Count

29 as on Aug 31, 2025

Similar Companies

HOOKIPA Pharma & 358 more

View Mynvax's full profile

Mynvax is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MYNVAX PRIVATE LIMITED CIN: U73200KA2017PTC102838 , India, Active	May 05, 2017	0 - ₹10 Cr (As on Mar 31, 2025)	33 (As on May 01, 2026)

Mynvax has raised a total funding of $9.82M over 5 rounds. Its first funding round was on Aug 07, 2018. Its latest funding round was a Series A round on May 24, 2024 for $*****. 2 investors participated in its latest round. Mynvax has 17 institutional investors and 57 angel investors.

Here is the list of recent funding rounds of Mynvax:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 24, 2024	3528950	Series A	4693976	7046517	1189903	9264900
Jul 08, 2021	8806957	Series A	9962228	5730276	9011575	LetsVenture & 19 more
Aug 01, 2020	3607077	Grant (prize money)	5761273	7304749	6992638	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Mynvax's funding rounds and investors

The founders of Mynvax are Raghavan Varadarajan and Gautham Nadig.

Here are the details of Mynvax's key team members:

Raghavan Varadarajan: Co-Founder of Mynvax. They are also an angel investor in 1 startup and serve on the board of 1 company.
Gautham Nadig: Co-Founder of Mynvax. They serve on the board of 1 company.

Mynvax's Board of Directors

Mynvax's board has 4 active members. Raghavan Varadarajan and Gautham Nadig are part of team and Anil Gudibande and Arun Suresh Chandavarkar are independent board members.

Here is the list of Mynvax's board of directors:

Name	Type	Representing	Status	Duration
Gautham Nadig	Team	-	Current	9y 2m
lcrldck	Team	-	Past	1y 8m
Arun Suresh Chandavarkar	Independent board member	-	Current	5y 6m
qxmzkmn	Independent board member	-	Past	1y 3m

View details of Mynvax's Founder profiles and Board Members

Mynvax's employee count trend

Mynvax has 29 employees as of Aug 25. The total employee count is 4.0% more than what it was in Aug 24. Here is Mynvax's employee count trend over the years:

Uncover Mynvax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mynvax include HOOKIPA Pharma, Vaxart and Atea. Here is the list of Top 10 competitors of Mynvax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	70/100
2nd	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	67/100
3rd	Atea 2014, Boston (United States), Public	Developer of therapeutics for viral diseases	$293M	GSA Capital Partners, Bain Capital & 18 others	67/100
4th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Yunfeng Capital & 7 others	63/100
5th	Leyden Labs 2020, Leiden (Netherlands), Series B	Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa	$303M	Google Ventures, Clavystbio & 14 others	63/100
6th	eradivir 2020, West Lafayette (United States), Series A	Developer of immunotherapies for the treatment of infectious diseases	$20.4M	Research Bridge Partners, National Science Foundation ... & 2 others	62/100
7th	Memo Therapeutics 2012, Schlieren (Switzerland), Acquired	Developer of antibodies for treating infectious diseases and cancer	$97.2M	Swisscanto, Verve Ventures & 17 others	61/100
8th	VBI Vaccines 2001, Cambridge (United States), Public	Developer of vaccines for the treatment of infectious diseases	$65.1M	RTW Investments, Perceptive Advisors & 7 others	60/100
9th	Ascletis 2011, Hangzhou (China), Series B	Developer of small molecules for the treatment of multiple diseases	$255M	CBC Group, Goldman Sachs & 5 others	60/100
10th	Ocugen 2013, Aurora (United States), Public	Developer of therapeutic solutions to treat various eye disorders	-	Checkmate Capital, Colorado Office of Economic Development and International Trade ... & 5 others	59/100
51st	Mynvax 2017, Bengaluru (India), Series A	Developer of novel recombinant vaccines to fight the human influenza virus and COVID19	$9.82M	LetsVenture, Accel & 72 others	48/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Mynvax's competitors? Click here to see the top ones

Founders (largest shareholder) own 30.70%, Funds own 20.12%, Enterprises own 10.99% and Angels own 24.78%. The net worth of Mynvax's founders is INR 40.2Cr as of Aug 13, 2021.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	30.70%	40.2Cr	5933546	1276047	6949038	5172613
Raghavan Varadarajan	3974221	9101200	1211383	9257256	1316992	6557374
Fund	20.12%	26.3Cr	4919563	2880044	6400006	5777182
Accel	5718051	2318389	4870806	2703106	5114610	8313529
Enterprise	10.99%	14.4Cr	2272444	8807203	8627362	4064994
Angel	24.78%	32.4Cr	9600955	9634187	9568671	1466410
Lakshminarayanan Subramanian	2	6	4	2	3	8
Other People	0.21%	27.2L	0	0	0	0
ESOP Pool	5.00%	6.54Cr	29046	46634	43511	35955
Total	91.80%	120Cr	3445226	6495414	9439896	6489873